bioRxivCancer Biology
Expression and in vitro anticancer activity of Lp16-PSP, a member of the YjgF/YER057c/UK114protein family from the mushroom Lentinula edodes C91-3
T. P. Joseph, Q. Zhao, W. Chanda, S. Kanwal, Y. Feng, M. T. Zhong, M. Huang
Abstract
Latcripin-16 (Lp16-PSP) is a gene that was extracted as a result of de novo characterization of the Lentinula edodes strain C91-3 transcriptome. The aim of the present study was to clone, express and investigate the selective in vitro anticancer potential of Lp16-PSP in human cell lines. Lp16-PSP was analyzed using bioinformatics tools, cloned in a prokaryotic expression vector pET32a (+) and transformed into E. coli Rosetta gami. It was expressed and solubilized under optimized conditions. The differential scanning fluorometry (DSF)-guided refolding method was used with modifications to identify the proper refolding conditions for the Lp16-PSP protein. In order to determine the selective anticancer potential of Lp16-PSP, a panel of human cancerous and non-cancerous cell lines was used. Lp16-PSP protein was identified as endoribonuclease L-PSP protein and a member of the highly conserved YjgF/YER057c/UK114 protein superfamily. Lp16-PSP was expressed under optimized conditions (37{degrees}C for 4 h following induction with 0.5 mM isopropyl {beta}-D-1-thiogalactopyranoside). Solubilization was achieved with mild solubilization buffer containing 2M urea using the freeze-thaw method. The DSF guided refolding method identified the proper refolding conditions (50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 400 mM Arginine, 0.2 mM GSH and 2 mM GSSG; pH 8.0) for Lp16-PSP, with a melting transition of ~58{degrees}C. A final yield of ~16 mg of purified Lp16-PSP from 1 L of culture was obtained following dialysis and concentration by PEG 20,000. A Cell Counting Kit-8 assay revealed the selective cytotoxic effect of Lp16-PSP. The HL-60 cell line was demonstrated to be most sensitive to Lp16-PSP, with an IC50 value of 74.4{+/-}1.07 g/ml. The results of the present study suggest that Lp16-PSP may serve as a potential anticancer agent; however, further investigation is required to characterize this anticancer effect and to elucidate the molecular mechanism underlying the action of Lp16-PSP.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PEBP1 is a candidate biomarker of response to the PP2A inhibitor LB-100
Matheus Henrique Dias, Chrysa Papagianni, René Bernards·bioRxiv·Feb 25, 2025
- PROTAC-Driven Protective Therapy increases the therapeutic window of anticancer drugs
Lucía Simón-Carrasco, Soledad Raya, … Andres Joaquin Lopez-Contreras·bioRxiv·Jan 13, 2026
- Targeting the Human Papillomavirus 16 E6 Oncoprotein with Antibodies
G. Dayer, A. Faulkner, … I. Zehbe·bioRxiv·Oct 21, 2022
- Leucine Aminopeptidase LyLAP enables lysosomal degradation of membrane proteins
Aakriti Jain, Isaac P. Heremans, … Roberto Zoncu·SciencePeer-reviewed·Mar 27, 2025
- The HPV E7 oncoprotein promotes LIM and SH3 Domain Protein 1 (LASP1) transcription via the Rb/E2F1 signalling pathway in HPV-positive cervical cancer cells
Miao Wang, Yigen Li, … Andrew Macdonald·bioRxiv·Apr 10, 2026
- Lysosomal membrane permeabilization enhances the anticancer effects of RNA Polymerase I transcription inhibitors
Lucille Ferret, Jonathan G. Pol, … Mojgan Djavaheri‐Mergny·AutophagyPeer-reviewed·Jun 18, 2025